Introduction P re-eclampsia (PE) is a complex multisystem disorder affecting 3-5% of pregnancies. 1 Early-onset pre-eclampsia that requires delivery before 34 weeks of gestation occurs in 0.5% of the population and is associated with significant short-term and long-term adverse outcomes to both mother and fetus. 2 15-25% of these women are at increased risk of cardiovascular disorders later in life. [3] [4] [5] Antenatal screening of pre-eclampsia has evolved significantly in the last decade. Although it is not clear that the screening and prevention of PE will decrease the long-term risk of cardiovascular disorders, there is enough evidence to suggest that high-risk pre-term PE can be effectively predicted in early pregnancy and preventative measures can be taken to reduce the prevalence of this condition and its associated morbidity. 6, 7 Pathogenesis The hypertensive disorders of pregnancy have been historically defined as a condition with headache, heaviness and convulsions. Since that description, significant research has been performed to understand the etiopathogenesis of pre-eclampsia however; the pathophysiology of the disease is still not well understood. It is accepted that the placenta plays a major role in the development of the disease as its delivery cures the condition. 8 Failure of the deep trophoblastic invasion and incomplete spiral artery remodelling is the initial step; however, what triggers this is largely unknown. 9, 10 Abnormalities in the placental microcirculation lead to hypoxia or ischaemia, resulting in the release of antiangiogenic molecules into the maternal circulation. This leads to widespread endothelial dysfunction, causing vasoconstriction, end-organ ischaemia and increased vascular permeability. [11] [12] [13] Placental hypoxia/stress leads to typical villous and vascular placental lesions, and these lesions are fourfold to sevenfold higher in pre-eclamptic than in normal pregnancies. These placental lesions also occur in fetal growth restriction (FGR) without pre-eclampsia, recurrent pregnancy loss, spontaneous preterm birth and normal pregnancies, making them less sensitive and specific to the diagnosis of PE.
14 PE with FGR has a significantly suppressed cardiac output (CO) starting from the early stages of pregnancy, suggesting that these pregnancies are affected by the failure of cardiovascular adaptation and the persistence of a low CO, high-resistance haemodynamic profile. It is speculated that placental dysfunction in PE could be secondary to maternal disorders/cardiovascular maladaptation. The failure of the maternal cardiovascular system to adapt to the pregnancy may be the primary mechanism causing secondary placental dysfunction. The heterogeneity of the disease reveals that both maternal and placental factors are involved in the pathogenesis. 15 
Screening
The incidence of pre-eclampsia in NSW is approximately 3.3%, which is similar to worldwide numbers. Identification of these women early in the pregnancy allows for preventative measures to be taken and appropriate plans can be made for monitoring and clinical management. 16 The traditional approach for screening is based on maternal demographics and medical, obstetrics and family history. The National Institute for Health and Care Excellence (NICE) and The American College of Obstetricians and Gynaecologist (ACOG) have issued guidelines based on these factors. 17, 18 The NICE guideline has a modest sensitivity of 80% for preeclampsia; however, the specificity is only 54% and positive predictive value (PPV) is 7%. This means almost half of the women screened would be considered to be at increased risk. The methods of NICE and ACOG treat each maternal factor as a separate screening test with additive detection rate (DR) and false-positive rate (FPR) with no provision of risk reduction with negative factors. Because of the low specificity and low PPV, it is difficult to justify their practical use in clinical practice. 19 A systematic review and meta-analysis of clinical factors that included 93 studies (N = 25 million) concluded that women with a prior history have the greatest pooled relative risk (8.4, 7.1-9.9) of pre-eclampsia. 20 However, this risk factor cannot be applied to nulliparous women -the group which has the highest incidence of pre-eclampsia. The parous women contribute to approximately 45% of the cases and 29% of these parous women have had no history of pre-eclampsia. Therefore, history alone is a poor predictor of pre-eclampsia in a general population. 21 Correspondence to email ritumogra@hotmail.com doi: 10.1002/ajum.12101
As abnormal placentation is a hallmark of pre-eclampsia, impaired trophoblast invasion of the maternal spiral arteries leads to high-resistance uteroplacental blood flow which can be measured by the uterine artery blood flow resistance. Giles et al. first noted the correlation between the uterine artery Doppler and adverse pregnancy outcomes in 1985. 22 Brosens et al. demonstrated from placental bed biopsy that placenta of hypertensive patients and babies with low birthweight illustrated an absence of physiological changes in the myometrial segment of spiral arteries.
9,10 A meta-analysis of 18 studies (N = 55974) concluded that the first-trimester uterine artery evaluation is a highly specific test (92%) for the prediction of early-onset preeclampsia with moderate sensitivity (48%). 23 The uterine artery RI or PI ≥ 90th centile and the presence of notching (unilateral/ bilateral) were used to define abnormal velocity waveforms. Poon et al. in a prospective study of 8366 singleton pregnancies demonstrated that in a multivariate regression model, the measurement of the lowest uterine artery PI increased the detection rate of early PE from 47% to 81% with a 10% FPR. 24 The inclusion of the uterine artery Doppler assessment lowers the FPR and provides a high negative predictive value.
The technique of the uterine artery Doppler in the first trimester is different from the second trimester. In the mid-sagittal section, using the colour Doppler, the right and the left uterine artery is identified along the side of the cervical canal at the level of the internal os as it travels cranially along the uterine body. 25 The uterine artery Doppler can be easily incorporated during the first trimester combined screening. Incorporation of uterine artery Doppler requires the appropriate training of sonographers, and the quality assurance programme is crucial. The standardised protocol for this has been established, and concordant normal ranges have been published for PI and RI at 11-14 weeks in the last decade. 23, 26 RI values have shown to have a high degree of intra-and interobserver reliability as compared to PI. Poon et al. examined whether it was best to use the mean PI of both uterine arteries, the highest PI or the lowest PI and found that there was no significant difference in these indices and the lowest PI was also significantly increased in pregnancies that subsequently developed gestational hypertension. 24 It is well known that women who develop PE have elevated BP during the first trimester and even before pregnancy. Because of differences in the methodology of measuring BP, there are varied results of screening performance with sensitivity ranging from 5% to 100% and FPR ranging from 0 to 66%. A systematic review of studies including more than 60,000 women and 3000 cases of PE concluded that the mean arterial pressure (MAP) is significantly superior to systolic or diastolic BP in predicting PE. 27 Poon et al. in a prospective study of 22,900 cases with 587 cases of PE demonstrated that the high performance of screening for PE can be achieved using the NHFA protocol by the simpler approach of using the average of two BP recordings from each arm. 28 In a multivariate analysis, the maternal history, uterine artery PI, and MAP increased the detection rate of early PE to 89.2% with 10% false-positive rate. 29 Maternal serum PAPP-A and PLGF are two biochemical markers that have been investigated extensively and have shown promising results in the early prediction of PE. The MoM values of PAPP-A and PLGF are lower at 11-13 weeks' gestation in women who subsequently develop PE. In isolation, these biomarkers have a very low sensitivity in predicting PE. 30, 31 No single test performs adequately in the prediction of preeclampsia. A multiple logistic regression model that includes maternal demographic factors, MAP, uterine artery Dopplers and the biochemical markers has the highest sensitivity of >90% and specificity of >95% in predicting early-onset preeclampsia. 32 The performance of this algorithm varies when applied to different population. This work has been validated in the different clinical settings and in our own Australian population and has shown similar performance.
33-35
Prevention Aspirin has shown to be beneficial in the prevention of preeclampsia. A recent meta-analysis of sixteen trials including 18,907 women demonstrated that aspirin administration in women at high-risk of PE is associated with a significant reduction in the risk of pre-term PE (RR 0.62; 95% CI: 0.45-0.87). The effect was more pronounced if aspirin was initiated <16 weeks and dose >100 mg was used and that lead to 70% reduction in pre-term pre-eclampsia. Aspirin is more beneficial in cases of pre-term PE and not in cases of late-onset mild disease suggesting different etiopathogenesis. 7 The exact mechanism of action of aspirin is not clearly known. PE women have increased excretion of thromboxane (TBX2). Aspirin has shown to shift the balance between TXA2 and prostacyclin, leading to vasodilation and enhanced blood flow. In addition to inhibitory effects on platelet aggregation and vasoconstriction, an anti-inflammatory effect has also been hypothesised. 36 The findings that aspirin is more beneficial if started <16 weeks explain that aspirin is more effective in reducing deep placentation disorders. The same beneficial effect is not present in women with chronic hypertension.
Using the FMF algorithm for predicting pre-eclampsia and using the 1:100 cut-off to define high-risk cases, only 10% of the population will be screen positive and receive aspirin. This would contain 75% of the population of those that will develop pre-term PE using FMF algorithm and only 39% and 5% of population using NICE and ACOG guidelines. ACOG and NICE probably target a different population as compared to the population defined by FMF algorithm. 37, 38 Aspirin is cheap and safe. Its safety has been tested for decades and recently evaluated in meta-analyses supporting its use beyond the first trimester with no evidence of an increased likelihood of maternal or fetal bleeding. [39] [40] [41] The beneficial effect of aspirin in the prevention of pre-term pre-eclampsia depends on the compliance as demonstrated from ASPRE trial where preeclampsia developed in only 0.9% of the population when compliance was >90% as compared to 3.3% of the population when compliance was less than 90%. 42 
Conclusion
Over several decades, antenatal screening for pre-eclampsia evolved steadily from the initial concept of history to complex protocols involving the combination of history, biomarkers and ultrasound parameters. Predictive algorithms have become more refined, and it is now possible to detect >90% of patients who are destined to develop pre-term PE. Obstetric services with well-established first-trimester screening services can easily incorporate PE screening. There is strong evidence that in a carefully selected population, using aspirin 150 mg at bedtime significantly reduces early-onset pre-eclampsia. The beneficial effect of aspirin depends upon the compliance, dose and the time of the day it is taken. The cost of intervention is minimal with a significant reduction in neonatal and maternal morbidity and mortality.
